Little is known about the molecular determinants of ovarian cancer, the fifth most common cause of cancer death in women. CpG island (CGI) hypermethylation is known to turn off gene expression and is associated with cancer progression. Our group used differential methylation hybridization, a microarraybased technique, to scan for alterations in methylation in ovarian cancer. We performed such screening of stage IIIC epithelial ovarian carcinomas (N=10), normal ovarian surface epithelial cells and ovarian cancer cell lines. A wide range of hypermethylated CGIs (2.5-fold increase; P <0.05) was seen in the ovarian carcinomas (23-98); however, the number of hypermethylated CGIs was similar across ovarian cancer cell lines (38-51). There were 12 hypermethylated CGIs (P<0.05) common to the ovarian cancer cell lines and tumors. Sequencing analysis revealed 11 methylated CGI tags in the ovarian tumors that had previously been shown to be hypermethylated in breast cancer. Tumor methylation levels before therapy were associated with patient response to chemotherapy (P=0.048; one-sided exact Wilcoxon rank sum test). Patients displaying a complete response had tumors with a low methylation score; conversely, patients with progressive disease had tumors with a higher methylation score. Although we have analyzed only a small fraction (2%) of the CpG islands in the human genome, we have found a relationship between the amount of methylation in ovarian tumors and response to chemotherapy. Our proof-of-concept study lays the foundation for genome-wide screening of methylation using DMH to examine epigenotypephenotype relationships in ovarian cancer.
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Genomic approaches to the development of prostate cancer diagnostics Soft-tissue sarcomas are tumors of mesenchymal origin that often constitute a diagnostic and therapeutic dilemma. Some soft-tissue sarcomas are characterized by specific chromosomal translocations. The resulting fusion transcripts typically encode aberrant transcription factors, and their pathogenic effects are likely to be mediated through their actions on gene expression. Based on this hypothesis we are investigating gene expression patterns in synovial sarcoma using complementary DNA microarrays containing 6,500 sequence-verified human cDNAs. The t(X; 18)(p11.2; q11.2) translocation is characteristic of synovial sarcomas and fuses the SYT gene to either SSX1 or SSX2. Expression analyses were performed on 16 synovial sarcomas confirmed to have either the SYT-SSX1 or SYT-SSX2 fusion transcript. Five other sarcoma samples, mostly malignant fibrous histiocytomas, were included as a comparison group. Hierarchical clustering analysis shows that these two tumor groups clearly separate with distinct expression patterns. One of the tumors, previously diagnosed as a synovial sarcoma, was closer to the malignant fibrous histiocytoma cluster. Analysis by means of the polymerase chain reaction with reverse transcription showed that this tumor was lacking the SYT-SSX fusion transcript, and the histological review reclassified it as a fibrosarcoma. This indicates that SYT-SSX-verified synovial sarcomas indeed have a specific expression profile. We are now attempting to determine the genes best able to define the synovial sarcoma cluster. Synovial sarcomas have two major histological subtypes, biphasic and monophasic, defined by the presence or absence of glandular epithelial differentiation in a background of spindle cells. Analyses of the genes discriminating monophasic from biphasic synovial sarcomas may also provide clues to the pathways regulating epithelial differentiation.
